5-yr-white-trans
  • HOME
  • ABOUT MORSE
    • The Team
    • Strategic Partners
      • Lorraine Boyle
      • Dominika Dabrowski
      • Stephen Filbey
      • Brent Korte
    • Careers
  • SERVICES
    • Our Services
    • Strategic Advice
      • MORSE pCPA Assessment
      • MORSE HTA Strategic Advice
    • Analyses
    • Advisory Boards
      • MORSE Advisory Panel (MAP)
    • Training
      • RWE/Innovative Agreements
      • Private Payer
      • Negotiation Simulation
      • Reimbursement Training
    • Reports
      • Canadian Reimbursement and Forecasting Timelines Report (CRaFT)
      • Drugs for Rare Diseases Sub-Report
      • Oncology and Biosimilar Sub-Report
  • NEWS
    • MORSE Signals
    • MORSE Wire
    • Publications
    • What’s New
  • EVENTS
  • LINKS
  • CONTACT US
logo-top-c-r
5-yr-white-trans
  • HOME
  • ABOUT MORSE
    • The Team
    • Strategic Partners
      • Lorraine Boyle
      • Dominika Dabrowski
      • Stephen Filbey
      • Brent Korte
    • Careers
  • SERVICES
    • Our Services
    • Strategic Advice
      • MORSE pCPA Assessment
      • MORSE HTA Strategic Advice
    • Analyses
    • Advisory Boards
      • MORSE Advisory Panel (MAP)
    • Training
      • RWE/Innovative Agreements
      • Private Payer
      • Negotiation Simulation
      • Reimbursement Training
    • Reports
      • Canadian Reimbursement and Forecasting Timelines Report (CRaFT)
      • Drugs for Rare Diseases Sub-Report
      • Oncology and Biosimilar Sub-Report
  • NEWS
    • MORSE Signals
    • MORSE Wire
    • Publications
    • What’s New
  • EVENTS
  • LINKS
  • CONTACT US

MORSE Strengthens Public Payer Expertise

September 7, 2021
-
Market Access News, What's New
-
Posted by MORSE - < 1 min read.

Toronto, September 7, 2021 – MORSE Consulting is pleased to announce the addition of Katherine Scott as a Consultant.

The Canadian public system remains one of the critical payers in this country’s pharmaceutical reimbursement pathway. This system is growing increasingly complex with new funding mechanisms for emerging gene and cell therapies, novel approaches related to outcomes-based agreements, evolving policies related to biosimilars, and variations in how provincial payers implement pCPA negotiations. As a result, there is a pressing need for stakeholders to benefit from a better understanding of the latest developments from a public payer perspective.

With the addition of Katherine Scott, MORSE Consulting further strengthens its strategic advice capabilities related to the public payer market. Katherine has more than 3 years of experience working for two Canadian public payers where she built extensive knowledge regarding public drug plans as well as the interplay with the overall pharmaceutical landscape. Her roles in both New Brunswick and Alberta supported public payer decision making and she was an active participant in pan-Canadian Pharmaceutical Alliance (pCPA) operations. She has led and supported numerous pCPA negotiations and subsequent product listing agreement implementation in both provinces. She was integral to the development and implementation of multiple policy initiatives, including the Alberta Biosimilar Initiative. Katherine’s background in economics, along with her experience with two public drug plans and the pCPA provide a unique and valuable perspective when working towards market access solutions.

 

 

As a Consultant, Katherine supports MORSE’s clients by providing public payer and pCPA insights to inform the development of their overall reimbursement strategy, including pCPA assessments, advisory board participation and simulated pCPA negotiation services.

Please contact Arvind Mani (arvind@morseconsulting.ca) or Sherry O’Quinn (sherry@morseconsulting.ca) to learn more about how the MORSE team can help address your reimbursement needs.

 

Share
Tags
CADTH
HTA
Market Access Strategy
MORSE Team
Oncology
pCPA
pCPAO
Pharmacare
Pharmaceuticals
PLA
PLAs
Reimbursement strategy
← PREVIOUS POST
Highly productive August with pCPA completing 10 negotiations
NEXT POST →
Files Under Consideration Holds Steady at 30

Contact Us
MORSE Consulting Inc.
Toronto | Ottawa, Canada
+1-647-717-3179 (Toronto)
+1-613-864-8645 (Ottawa)
info@morseconsulting.ca
Social
Connect & Follow:

New Report

Newsletter – MORSE Signals
Sign up for our free e-mail newsletter service and receive timely and relevant updates related to the emerging developments in the Canadian pharmaceutical reimbursement landscape.

Sign Up
MORSE Consulting Inc. | Deciphering Canadian pharmaceutical market access signals to create reimbursement success.
© 2022 MORSE Consulting Inc. All rights reserved. | Site by Directica Media
MORSE Strengthens Public Payer Expertise